Flagship startup Alltrna raises $109M for tRNA therapies that restore missing proteins
09 Aug 2023
Alltrna, a startup founded by Flagship Pioneering, has raised $109 million in Series B financing to develop a new class of genetic medicines based on transfer RNA molecules. It’s the largest round of funding yet for a company focused on ushering in an emerging class of genetic therapies that promises to override disease-causing mutations.
Although tRNA is well-known to biologists for its vital role in translating the messenger RNA code into proteins, the molecules have received little attention from biotech companies until relatively recently. Alltrna, hC Bioscience and Tevard Biosciences are among startups tinkering with tRNA.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.